BioNTech touts differences with Moderna in race for cancer vaccines

BioNTech chief strategy officer Ryan Richardson highlighted the differences between his company’s cancer vaccine and another under development by Moderna and Merck, as the companies race each other for a piece of what could be a major new class of products.